We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Statins Slow Growth of Cancers with p53 Structural Mutations

By LabMedica International staff writers
Posted on 08 Feb 2017
Print article
Image: Atorvastatin bound to HMG-CoA reductase (Photo courtesy of Wikimedia Commons).
Image: Atorvastatin bound to HMG-CoA reductase (Photo courtesy of Wikimedia Commons).
Cancer researchers have demonstrated the ability of cancer-lowering statin drugs to slow the growth of certain types of cancers with p53 mutations.

Most cancers fail to propagate unless the p53 gene is inactivated through mutation, or if the p53 protein becomes inactivated. Investigators at the University of Kansas Medical Center looked for chemical compounds that could inhibit the activity of structurally mutated p53 proteins that can accelerate cancer progression, while not harming proteins produced by healthy p53 genes.

Toward this end, the investigators screened nearly 9,000 compounds - including 2,400 that were [U.S.] Food and Drug Administration-approved drugs – to identify any that might degrade mutant p53.

The investigators reported in the November 2016 issue of Nature Cell Biology that statins, cholesterol-lowering drugs such as Lipitor (atorvastatin), Crestor (rosuvastatin) and Mevacor (lovastatin), were degradation inducers for conformational or misfolded p53 mutants with minimal effects on wild-type p53 (wtp53) and DNA contact mutants. The statins impacted only structurally mutated (misfolded) p53, as opposed to p53 mutated at the site of DNA binding.

Statins act by competitively inhibiting the enzyme HMG-CoA reductase, the first committed enzyme of the mevalonate pathway. Because statins are similar in structure to HMG-CoA on a molecular level, they fit into the enzyme's active site and compete with the native substrate (HMG-CoA). This competition reduces the rate by which HMG-CoA reductase is able to produce mevalonate, the next molecule in the cascade that eventually produces cholesterol. By inhibiting HMG-CoA reductase, statins block the pathway for synthesizing cholesterol in the liver.

In the current study, the investigators found that specific reduction of mevalonate-5-phosphate by statins induced CHIP (C terminus of HSC70-Interacting Protein) ubiquitin ligase-mediated nuclear export, ubiquitylation, and degradation of mutated p53 by impairing interaction of this protein with DNAJA1 (DNAJ heat shock protein family (Hsp40) member A1). DNAJA1 a member of the DNAJ family of proteins, which act as heat shock protein 70 co-chaperones. Heat shock proteins facilitate protein folding, trafficking, prevention of aggregation, and proteolytic degradation. Members of this family are characterized by a highly conserved N-terminal J domain, which mediates the interaction with heat shock protein 70 to recruit substrates and regulate ATP hydrolysis activity. Knockdown of DNAJA1 induced CHIP-mediated mutated p53 degradation, while its overexpression prevented statin-induced degradation of this protein.

In a study in which mice carrying human tumors expressing mutant p53, were treated with high doses of statins for 21 days, it was found that the tumors grew poorly in mice treated with statins compared to the controls, and that the statins worked only on structurally mutated p53, as opposed to p53 mutated at the site of DNA binding.

"We found that only the structural mutation is affected," said senior author Dr. Tomoo Iwakuma, associate professor of cancer biology at the University of Kansas Medical Center. "Which explains why clinical studies with statins were inconclusive. Mutant p53 makes human cancer cells more metastatic and resistant to chemotherapy. That is a primary reason to get rid of it -- to improve survival in cancer patients."

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.